DAVITA (DVA) 10-K Summary — Year Ended Dec 31, 2023
DaVita Inc. provides kidney care services, primarily through dialysis centers. The financial year showed higher revenue and operating cash flow, while net income grew notably.
Key takeaway
Year ended Dec 31, 2023 · FY2025 10-K
DaVita Inc. provides kidney care services, primarily through dialysis centers. The financial year showed higher revenue and operating cash flow, while net income grew notably.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$12.1B
Revenue reported for the fiscal year.
Operating income
$1.6B
Income from operations reported for the year.
Net income
$691.5M
Net income reported for the year.
Operating cash flow
$2.1B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $11.6B | n/a |
| Dec 31, 2022 | $11.6B | -0.1% |
| Dec 31, 2023 | $12.1B | +4.6% |
Business overview
DaVita operates as a provider of kidney dialysis services for patients with chronic kidney failure. The company's business overview is described in Item 1 of its 10-K filing, covering the operation of dialysis centers and related healthcare services.
Financial performance
Annual revenue increased from the prior period, and operating income remained positive. Operating cash flow was robust relative to revenue, and net income showed improvement over the year.
Material risks
The filing highlights risk factors in Item 1A, including regulatory changes, reimbursement policies, and competitive pressures. These factors could affect the company's operations and financial results.
Liquidity and capital
The company's liquidity and capital resources are discussed under the Management Discussion and Analysis section, indicating ongoing cash generation to support operations and obligations.
What to watch
Monitor the next filing for any updates on regulatory or reimbursement changes that could impact dialysis service revenue.